Sept 8 (Reuters) - Bristol Myers Squibb said on Tuesday its experimental cell therapy for a type of blood cancer had met the main goal of a mid-stage trial. The company was testing the therapy, called ...
FDA on Thursday approved Bristol ‌Myers Squibb's combination treatment for ‌patients with a rare form of blood ​cancer whose illness had relapsed or not responded to other treatments, the health ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results